OBJECTIVES: To assess the cost-effectiveness of ferric carboxymaltose (FCM) and iron sucrose (IS) in the correction of iron-deficiency anaemia (IDA) before elective major surgery in non-cardiac surgical patients and predict potential budget expenses for the day care services and blood transfusions. METHODS: The pharmacoeconomic model was developed based on the data from multicentre prospective study (E. Bisbe et al., 2011) on the efficacy of FCM and IS for correcting preoperative anaemia in patients undergoing major elective non-cardiac surgery. The cost-effectiveness of two intravenous iron formulations was measured as total costs of medicines and day care services per one patient attained iron replenishment or per one patient without IDA at the end of treatment. Budget impact analysis included expenses for the day care services and blood transfusion procedures during intraoperative and/or postoperative period. Sensitivity analysis was performed by including in the model of iron sucrose similars (ISSs). It was considered that treatment with ISSs requires dose increase up to 120-135% of dose of the original IS (E. Lee et al., 2013; J. Rottermbourg et al., 2010).  RESULTS: The clinical efficacy of FCM was higher compared to that of IS, this was also reflected in better pharmacoeconomic profile of FCM. The CERs were 14,473.61 RUB and 15,222.83 RUB per one patient attained iron replenishment in the FCM and IS groups, respectively. Treatment with FCM was associated with 2.5-fold lower costs of day care services and 2.7-fold lower expenses for blood transfusion procedures. Additional expenses for the day care services were required for patients received ISSs due to increased frequency of injections; this was resulted in the highest CERs in the ISS group.  CONCLUSIONS: The present study has demonstrated that administration of FCM is economically effective strategy to replenish body iron stores and correct IDA in surgical patients.